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Patterns of urinary f32-microglobulin excretion in patients
treated with aminoglycosides. Aminoglycoside antibiotics are rel-
atively mild nephrotoxins, but their action is site-specific to the
proximal tubule. Therefore, use of these drugs presents a unique
opportunity to study the temporal relation between the damage
to the cells lining the renal proximal tubule and the subsequent
rise in the serum creatinine concentration. Our study of 52
aminoglycoside-treated patients included measurements of daily
serum creatinine, daily 24-hour urinary /32-microglobulin (/32M)
excretion, and determination of aminoglycoside tissue accumula-
tion. An elevation in f3,M excretion above the baseline value oc-
curred in 37 of 52 (71%), whereas the serum creatinine concen-
tration rose in only 17 of 52 (33%) of patients. Even fewer pa-
tients (10 of 52) demonstrated all three criteria for
aminoglycoside nephrotoxicity. These 10 patients had elevated
tissue accumulation, evidence of renal tubular damage, and a rise
in serum creatinine concentration. The increased 32M excretion
greater than 50 mg/day preceded the serum creatinine rise by 2 to
7 days. An abnormal baseline $2M was not a risk factor for a
subsequent rise in creatinine concentration or vice versa. Al-
though each test is primarily site specific, widespread and severe
renal proximal tubular damage, regardless of cause, will even-
tually lead to an elevation of serum creatinine. Thus, serial mon-
itoring of proximal tubular function with urinary f32M excretion
has potential value in the assessment of insults to this site, but
cannot be expected to explain all changes in serum creatinine.
Modalités de l'excrétion urinaire de /32-microglobulines chez les
malades traités par les aminoglycosides. Les aminoglycosides ont
une action nephrotoxique de sëvéritd moyenne specifiquement
localisde au tube proximal. L'emploi de ces drogues offre
l'opportunite d'étudier Ia relation dans le temps entre la lesion
des cellules tubulaires proximales et l'elévation consecutive de
la créatininémie. L'étude de 52 malades traités par les amino-
glycosides a comporté Ia determination quotidienne de Ia créati-
ninemie et de l'excrCtion urinaire de 2-microglobu1ine W2M)
ainsi que Ia determination de l'accumulation tissulaire
d'aminoglycoside. Une elevation de l'excrétion de /32M au des-
sus de Ia valeur basale a ete observée chez 37 malades (7 1%)
alors que l'Clévation de la créatinine n'est survenue que chez 17
malades (33%). Dix malades seulement ont eu les trois critères
de nephrotoxicite par l'aminoglycoside. Ces 10 malades avaient
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une accumulation tissulaire, des signes de lesions tubulaires et
une elevation de Ia créatinine. Une augmentation de l'excrétion
de 32M, au dessus de 50 mg124 hr a précédé de 2 a 7 jours
l'elévation de Ia creatinineniie. Une excretion basale anormale
de p2M n'est pas un facteur de risque d'elevation ultérieure de Ia
crëatininemie, ou reciproquement. Bien que chacun de ces tests
soit specifique d'un site. des lesions tubulaires proximales sév-
ères et étendues doivent determiner une elevation de Ia créati-
nine, quelle que soit leur cause. La surveillance iterative de Ia
fonction tubulaire proximale par Ia mesure de l'excretion un-
naire de 2M a une valeur potentielle dans l'évaluation des le-
sions mais ne peut pas expliquer Ia totalite des modifications de
Ia creatininemie.
Amirioglycoside antibiotics cause dose-related
damage to the cells lining the renal proximal tubule
[1, 2]. Their nephrotoxicity is best understood in re-
lation to their pharmacokinetic disposition, as all
aminoglycosides accumulate to high concentrations
in the renal cortex [3—5] and persist there for
weeks to months following cessation of treatment
[6—9]. Patients treated with these agents are mon-
itored by measuring either their serum antibiotic or
their serum creatinine concentrations, but rising or
excessive serum creatinine levels are late markers
of aminoglycoside nephrotoxicity in both man [10,
11] and animals [1, 2, 12].
It has been proposed that following an insult to
the renal tubules, the glomerular filtration decreases
in response to a failure of renal proximal tubular
reabsorptive capability [13-17]. Aminoglycoside
nephrotoxicity is specific to ihe renal proximal tu-
bule, and although the mechanism is unknown, pa-
tients with aminoglycoside-induced nephrotoxicity
demonstrate a 3- to 7-day lag time between early
damage and subsequent rise in serum creatinine
concentration [10, 18—20]. Because this lag time al-
lows observation of several stages of damage,
aminoglycoside antibiotics, as relatively mild renal
proximal tubular toxins, offer a unique opportunity
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to study the sequence of events between renal tubu-
lar damage and the decline in glomerular filtration.
Aminoglycoside-associated renal tubular damage
occurs even in patients with normal baseline renal
function [10, 21, 22]. Of greater concern, the dam-
age can occur also in patients whose dosages are
adjusted to maintain safe" peak and trough drug
concentrations [10, 11, 22]. Because close mon-
itoring of blood aminoglycoside and serum creati-
nine concentrations may not always prevent renal
damage, an urgent clinical need exists for a more
sensitive test that reflects the proximal tubular site
of damage. Damage to renal tubules during therapy
can be monitored by urinary enzyme excretion [18,
23, 24], urinary cast excretion [19, 25], or by the
urinary loss of small molecular weight proteins,
such as /32-microglobulin (32M) [26, 27]. All of these
indices are more specific and earlier indicators of
renal tubular damage than is the serum creatinine
concentration [10, 27]. None of these renal tubular
indices, however, can distinguish aminoglycoside
effects from other clinical insults [10, 19. 24, 25, 27].
In the absence of a specific test for amino-
glycoside nephrotoxicity, a choice among the avail-
able methods for monitoring damage to the renal
proximal tubule might be made on relative sensitivi-
ty. Before this decision can be made, however, cor-
relation must be established between the urinary
excretion of each of the tubular indices and the sub-
sequent rise in serum creatinine concentration. To
this end, we evaluated 52 seriously ill patients by
daily 24-hour urine collections for j32M excretion.
Our goals were to assess the value of /32M in the
detection of the early stages of renal tubular damage
that lead to the elevation of serum creatinine con-
centration, and to establish the level of urinary f39M
excretion that would serve as a critical value in the
prediction of a subsequent creatinine rise.
Methods
Fifty-two patients (29 males, 23 females) aged 65
14 years, were treated 9.5 5.5 days with amino-
glycoside antibiotics for serious gram-negative in-
fections. Of the 52 patients, 18 (35%) were given
gentamicin, 27 (52%) were given tobramycin, and 7
(13%) were given amikacin. Dosages of these agents
were adjusted to yield therapeutic peak and trough
serum concentrations by means of nomograms and
serum assays. All patients were treated in intensive
care units for pneumonia, septicemia, or abdominal
infections complicating major surgery, or for infec-
tions complicating exacerbation of major medical
disorders, including congestive heart failure, diabe-
tes, liver disease, gastrointestinal bleeding, and
chronic lung disease. In addition to aminoglycoside
therapy, /3-lactam antibiotics or clindamycin were
also given, concurrently, to most patients with in-
fections. Of the 52 patients, 21 were given ceph-
alosporins, and 36 (69%) were given furosemide.
The serum creatinine concentration was mea-
sured daily by standard autoanalyzer methods, and
the upper limit of normal was 1.5 mg/dl for this
method. The pretreatment serum creatinine con-
centration averaged 1.4 0.9 in the 52 patients, and
the 24-hour creatinine clearance values averaged 61
20 ml/min. These values indicate mild renal dis-
ease in most patients and likely reflect the advanced
age of our 52 patients. A further serum creatinine
concentration increase of 0.5 mgldl was defined as a
significant change in glomerular filtration.
Urinary /32M excretion was measured before
treatment and daily from 24-hour urine collections,
and was assayed with a commercially available ra-
dioimmunoassay (Pharmacia, Piscataway, New Jer-
sey). All urine samples were alkalinized with 1.0 N
sodium hydroxide to prevent /32M degradation prior
to assay [28]. Values were plotted versus time to
evaluate patterns of excretion and changes in excre-
tion rate. The baseline period was the 1- to 2-day
period before treatment was started. Urinary f32M
excretion was considered normal if it was below 1.0
mg/day [26, 27]. Elevations in 32M were defined as
increases of 1.0 mg/day or greater above baseline.
Aminoglycoside serum concentrations were mea-
sured by radioimmunoassay (Monitor Science,
Newport Beach, California). Therapeutic peak and
trough serum concentrations were considered to be
10.0 and 2.0 pg/ml for gentamicin and tobramycin,
and 25.0 and 6.0 pg/m1 for amikacin. Amino-
glycoside tissue accumulation was calculated from
pharmacokinetic analysis with a two-compartment
model, as previously described [29]. High values for
aminoglycoside tissue accumulation were those
amounts above 200 mg for gentamicin, above 175
mg for tobramycin, and above 600 mg for amikacin
[10, 30]. Tissue accumulation was confirmed by
analysis of aminoglycoside urinary recovery after
the final dose, or by postmortem tissue analysis [5,
6, 10, 29, 30]. The majority of the calculated tissue
accumulation is found in the kidney, and the proxi-
mal tubular concentrations are probably reflective
of this calculated value [5, 29].
Results
Patterns of excretion and order of magnitude. In-
spection of the daily j32M values in each of the 52
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patients revealed several distinct temporal patterns
of f32M excretion. The three most frequently en-
countered patterns are illustrated in Fig. 1.
A patient with a marked f32M response to amino-
glycoside exposure is shown in the top frame. The
/32M excretion rapidly increased to above 50 mg/
day, continued to rise over the entire course of gen-
tamicin treatment, and declined only as serum
creatinine concentration began to rise rapidly. Of
the 52 study patients, 8 demonstrated a similar f32M
pattern. Of the 8, 7 were elderly obese women, 5 of
the 8 had diabetes, all received furosemide, and 6
were given, concurrently, cephalosporins. None of
the patients had positive blood cultures, severe
dehydration, or shock.
A significant rise in serum creatinine concentra-
tion occurred in only 3 of these 8 patients, in spite
of the multiple renal insults and the markedly ele-
vated 132M excretion. In these 3 patients, the /32M
excretion remained elevated until the serum cre-
atinine concentration rose; then it decreased. In the
other 5, /32M fell to normal within 10 days following
the last aminoglycoside dose.
Of the 52 patients, 21 had f32M excretion patterns
1 0 similar to the middle frame. Of these 21, 8 received• r cephalosporins, 14 received furosemide, 8 had dia-
o betes, 8 had shock, and 8 had positive blood cul-
tures. There were 11 males and 10 females; all were
4.0 older patients with severe infections. Of these 21
patients, 10 had an increase in serum creatinine
3.0 concentration. Of these 10, 7 had f32M excretions
: above 50 mg/day. Of the remaining 11 patients with-
out creatinine rise, 6 also had $2M excretions above
50 mg/day.
1.0 The pattern of/32M excretion for the remaining 23
patients is shown at the bottom of Fig. 3. This pat-
tern is qualitatively similar to that noted in the top
40 frame, but the excreted amount of/32M is far lower.
These 23 patients were apparently more tolerant of
aminoglycoside treatment, but did not differ from
the other two groups in clinical presentation. Of
these 23, 7 received cephalosporins, 14 received fu-
rosemide, 9 had diabetes, 6 had shock, and 5 had
positive blood cultures. There were 15 males and 8
females; all were elderly patients with complicated
infections. Only 4 of these 23 patients had a signifi-
cant rise in serum creatinine concentration, and of
these 4, only 1 had a creatinine rise that was preced-
ed by elevated /32M excretion above 50 mg/day. In
the group of 23 patients at the bottom of Fig. 3, only
2 had f32M elevations above 50 mg/day. One patient
experienced a /32M elevation without a serum
creatinine rise, and the other had an increase in
serum creatinine preceded by a /32M rise above 50
mg/day.
Most of the 52 patients reached this peak /32M ex-
cretion in the first 4 days of aminoglycoside treat-
ment, as shown at the top of Fig. 2, whereas a small
number of patients required as many as 8 to 11
days. The majority of patients also had peak excre-
tion values below 25 mg/day, with a few individuals
excreting up to 225 mg/day, as shown in the center
frame of Fig. 2. Finally, 132M values in most patients
returned to baseline values within 1 to 3 days after
the last dose of aminoglycoside.
Changes in serum creatinine. All 52 patients were
initially evaluated in terms of their baseline serum
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Fig. 1. Three typical patterns of $M excretion noted in this
study. Open circles represent the /32M excretion rate, and closed
circles represent the serum creatinine concentration. The amino-
glycoside and concurrent antibiotics given are indicated on the
graph. All values are plotted versus time in days.
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Fig. 2. Classification of the 52 study patients under time to peak
excretion (top), magnitude of peak excretion (center), and time
to return to baseline values after cessation of treatment (bottom).
creatinine concentrations. As shown in Fig. 3, of
the 52 patients, 13 (25%) had baseline serum creati-
nine concentrations above the laboratory range for
normal. During aminoglycoside treatment, 6 pa-
tients with elevated baseline creatinine concentra-
tions had further creatinine increases, compared to
11 patients with normal baseline values. The dif-
ferences are not significant (x2 = 1.42, P = NS).
During treatment, elevations of serum creatinine
concentrations were noted in fewer study patients
than were elevations of $2M. Of the 52 patients, 17
(33%) had an elevation in creatinine concentration,
but 37 (7 1%) had an increase in /32M excretion
above the normal range. Rises in /32M always oc-
curred prior to the serum creatinine rise, but a f32M
rise was not always followed by an elevation in the
serum creatinine during aminoglycoside treatment
(Fig. 3).
Prediction of serum creatinine rise from f3M rise.
The baseline /32M excretion and subsequent
changes in the 52 patients are illustrated in Fig. 4.
Thirty-one patients (60%) had baseline /32M above,
and 21 patients had baseline values below 1.0 mg/
day. The baseline elevations of most patients were
mild, as only 13 of the 31 patients with abnormal
/32M baseline values had /32M values above 10.0 mg/
day. During aminoglycoside therapy, 37 patients
had a f32M increase over the baseline values, and
patients with /32M rises were equally divided be-
tween baseline groups, as shown in Fig. 4. Because
these differences were not significant (x2 = 0.43, P
= NS), no greater incidence of f32M rise occurred in
patients with abnormal baseline f32M values. Only 5
of the 52 patients had a normal baseline f32M con-
centration that remained unchanged, which demon-
strates the almost universal renal tubular effects of
disease or treatment in these seriously ill patients.
Figure 4 also shows the serum creatinine re-
sponse of the study patients during aminoglycoside
therapy. Seventeen study patients (3 1%) had a
serum creatinine rise during aminoglycoside treat-
ment, but these 17 patients showed no differences
between f32M baseline groups in their subsequent
incidence of creatinine rise (x2 = 1.65, P NS). As
such, an elevated baseline 32M cannot be consid-
ered a risk factor for a further creatinine rise in pa-
tients given aminoglycosides.
In contrast to the patients with a /32M rise from
baseline, only 1 of the 15 patients with falling or un-
changed /32M excretion had a creatinine elevation.
This was true whether or not the /32M concentration
was abnormal at the baseline measurement. There-
fore, a low stable /32M excretion, or a decreasing
f32M excretion rate is unlikely to herald a later rise
in serum creatinine concentration in amino-
glycoside treated patients (Fig. 4).
In summary, most patients with a J32M concentra-
tion rise did not have a subsequent rise in their
serum creatinine concentration. Furthermore, an
abnormal /32M baseline in aminoglycoside-treated
patients was not more predictive of a subsequent
creatinine rsie than was a normal f32M baseline val-
ue.
Relations between /32M and aminoglycoside tis-
sue accumulation. The fourth division of both Figs.
3 and 4 shows data on accumulation of amino-
glycoside in tissue. In Fig. 3, a high tissue accumu-
lation was found in 2 patients with abnormal base-
line serum creatinine concentrations and in 8 pa-
tients with normal baseline serum creatinine
concentrations. In 9 of these 10 patients, this ele-
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vated tissue accumulation was observed in associa-
tion with a rise in both urinary f32M excretion and in
serum creatinine. These 9 patients fit our criteria for
aminoglycoside nephrotoxicity [10, 30]. The tenth
patient had a creatinine rise of 0.4 mg/dl, and is also
likely to have had aminoglycoside nephrotoxicity.
Tissue accumulation in association with a base-
line /32M excretion is illustrated in Fig. 4. Of the 31
patients with abnormal baseline f32M, 8 demon-
strated high tissue accumulation, whereas high tis-
sue accumulation was noted in 2 of the 21 patients
with normal baseline /32M excretion. Because this
trend is not statistically significant (x2 = 2.14, P =
NS), baseline tubular dysfunction does not pre-
dispose patients to abnormally high tissue accumu-
lation, at least in situations where aminoglycoside
blood levels are maintained within the recommend-
ed range.
Comparing the tests for serum creatinine, urinary
/32M, and tissue accumulation, our data indicate the
greatest sensitivity to be for f32M, as 71% of these
aminoglycoside-treated patients has a /32M rise,
compared with 33% having a creatinine rise, and
only 10% having an elevated tissue accumulation.
Because only half of the patients with both renal
tubular damage and elevated serum creatinine con-
centrations had elevated tissue accumulation, we
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postulated that only half of the treated patients with
an elevation in serum creatinine had amino-
glycoside-related renal damage. In the remainder,
we ascribed the renal damage primarily to the clini-
cal condition, or possibly as having been aggravated
by the aminoglycoside treatment.
Thus, in the assessment of aminoglycoside neph-
rotoxicity, 2M is a very sensitive but not specific
test. Elevated tissue accumulation is most specific,
yet difficult to assess routinely. The measurement
of serum creatinine is insensitive and nonspecific,
but universally available.
Discussion
The reabsorptive function of the healthy renal
proximal tubule includes the active uptake and ca-
tabolism of small-molecular-weight proteins such as
/32-microglobulin (/32M) [26, 28, 31, 32]. Reabsorp-
tion of filtered 32M is so efficient that normal uri-
nary losses are below 1.0 mg/day [27, 28].
After filtration by the glomerulus, /32M is bound
to the brush border membrane of the proximal tu-
bule, and high concentrations of basic amino acids
such as lysine will act as a competitive inhibitor
[33]. Competitive binding at the membrane level has
been demonstrated between aminoglycosides and
lysine, but only at lysine levels sufficient to saturate
Fig. 3. Grouping of the 52 study patients based on baseline serum creatinine values. The first division classifies the baseline serum
creatinine concentration, the second documents whether the serum creatinine concentration rose, fell, or was unchanged (unch) during
aminoglycoside treatment. The third division gives /32M changes preceding the change in serum creatinine, and specifically refers to
changes in /32M from baseline through the aminoglycoside treatment period. The fourth division (unlabeled) gives aminoglycoside tissue
accumulation during treatment. High values were above 200 mg for gentamicin, above 175 mg for tobramycin, and above 600 mg for
amikacin.
Urinary /32-nzicro globulin and aininogivcosides 659
Baseline I2 M
Normal = 21
132M rose 32Munch
(N=1161 (N=51
creatinine
I I
rose unch fell
5 8 3III I
low high low high
3 2 3 0
low high
8 0
All patients
(N= 521
Baseline l2 M
Abnormal 31
rose 132M fall
lNr2ll (N10)
creatinine
rose unch fell
11 6 4
low high low high
lcw high
0
creatine
rose unch fell
0 10 0
ch fell
I 0
the lysine reabsorptive site [34]. Competitive inhibi-
tion could occur between /32M and aminoglycosides
as well, because we have noted that f32M excretion
rate fluctuates in the interval between amino-
glycoside doses (unpublished observations). Be-
cause of these fluctuations, the 2M excretion rate
must be quantitated in terms of the amount per day
to interpret values. Competition for reabsorptive
sites alone, however, is an unlikely explanation for
the increased /32M loss in aminoglycoside-treated
patients, because even though the daily filtered load
of /32M is similar to the filtered amount of amino-
glycoside, far more 132M molecules are reabsorbed.
Because structural damage to the proximal tubule
is minimal after I to 3 days of treatment [2, 20, 35],
failure of /32M reabsorption could also be consid-
ered an early defect in tubular function, which
would lead to structural damage as the drug ex-
posure continued. If urinary f32M were a marker of
reabsorptive function, any insult that impairs the
ability of the proximal tubule to reabsorb small-mo-
lecular-weight proteins might also result in an ele-
vated /32M excretion rate [36—38]. It may require a
more severe renal tubular insult to elevate the con-
centration of creatinine, because 71% of amino-
glycoside-treated patients had some elevation of
f32M, but only 33% had a rise in serum creatinine.
The patient population chosen for our study un-
doubtedly includes a higher percentage with renal
low high
9 1
tubular damage than would be found in a randomly
selected group of hospitalized patients. f32M rose in
almost all aminoglycoside-treated patients. These
/32M increases might be common, because the drugs
aggravate the renal tubular functions of many older
critically ill patients. Alternatively, the increases
may reflect the sensitivity of this test to detect trivi-
al impairment in proximal tubular functions.
Our study suggests that a f32M excretion of 50 mg/
day is appropriate to define renal tubular damage in
most situations. No chosen /3M value, however,
can be expected to predict all serum creatinine ele-
vations, because the serum creatinine concentra-
tion might also rise when the GFR changes without
prior renal tubular damage.
/32M is readily measured by means of a sensitive
and commercially available radioimmunoassay. Its
extreme sensitivity to defects in proximal tubular
function allows quantitation of subtle changes in-
duced by drugs and environmental toxins [36-38].
Although /32M is not a specific test for amino-
glycoside nephrotoxicity, this same disadvantage is
also shared by renal enzymes, cast excretion, and
all other methods devised to monitor drug effects on
the renal tubule. Serum creatinine, other tests of
glomerular filtration, and aminoglycoside trough
levels are even less specific for tubular damage
than is /32M, and are also less sensitive. These
markers of glomerular filtration merely confirm, ret-
minecrea'
rose ur
low high1-
low high
4 0
Fig. 4. Grouping of the 52 study patients based on their baseline f32M values. The first division classifies patients based on normal or
abnormal baseline f32M. An abnormal baseline /32M was above 1.0 mg/day. The second division gives the course of 132M excretion during
the aminoglycoside treatment period. Values either rose, fell, or remained unchanged. The third division gives the resulting course of
serum creatinine during the aminoglycoside treatment. Values either rose  0.5 mg/dl, fell  0.5 mgldl, or remained stable (fluctuations
between 0.5 mg/dl). The fourth division (unlabeled) gives the aminoglycoside tissue accumulation in each of the patients. High values
were above 200 mg for gentamicin. above 175 mg for tobramycin. and above 600 mg for amikacin.
 
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rospectively, that tubular nephrotoxicity has oc-
curred.
Our serial use of /32M has revealed its exceptional
sensitivity, and also has provided insight into the
renal tubular insults that occur in acutely ill patients
given aminoglycosides. The use of this test reveals
subtle changes in tubular function of most amino-
glycoside-treated patients, and its potential value in
the study of proximal tubular dysfunction remains
an important area for further exploration.
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